相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Talia Golan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer
Tomohiro Kondo et al.
Oncotarget (2018)
Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX
Amikar Sehdev et al.
CLINICAL CANCER RESEARCH (2018)
Familial pancreatic cancer: Concept, management and issues
Hiroyuki Matsubayashi et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2017)
Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast Cancer
Eric Y. Zhao et al.
CLINICAL CANCER RESEARCH (2017)
The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer
Mark M. Pomerantz et al.
CANCER (2017)
PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy
Sharlene Gill et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Germline mutations in Japanese familial pancreatic cancer patients
Erina Takai et al.
ONCOTARGET (2016)
Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer
S. Ohkawa et al.
BRITISH JOURNAL OF CANCER (2015)
Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma
David Fogelman et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma
Spring Holter et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Whole genomes redefine the mutational landscape of pancreatic cancer
Nicola Waddell et al.
NATURE (2015)
Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
T. Golan et al.
BRITISH JOURNAL OF CANCER (2014)
Phase II study of FOLFIRINOX for chemotherapy-naive Japanese patients with metastatic pancreatic cancer
Takuji Okusaka et al.
CANCER SCIENCE (2014)
Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas
Kathryn P. Pennington et al.
CLINICAL CANCER RESEARCH (2014)
Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial
Helmut Oettle et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Multicenter Phase II Study of Gemcitabine and S-1 Combination Therapy (GS Therapy) in Patients With Metastatic Pancreatic Cancer
Hideki Ueno et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine As First-Line Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 Study
Giuseppe Colucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group
Elizabeth Poplin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase 2 Trial of Oxaliplatin Plus Capecitabine (XELOX) as Second-line Therapy for Patients With Advanced Pancreatic Cancer
Henry Q. Xiong et al.
CANCER (2008)
A late phase II study of S-1 for metastatic pancreatic cancer
Takuji Okusaka et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Phase II study of combination chemotherapy with gemcitabine and cisplatin for patients with metastatic pancreatic cancer
Hideki Ueno et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2007)
A phase II study of weekly irinotecan as first-line therapy for patients with metastatic pancreatic cancer
Hideki Ueno et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer
Volker Heinemann et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer:: Results of a GERCOR and GISCAD phase III trial
C Louvet et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds
AP Klein et al.
CANCER RESEARCH (2004)
Randomized phase II comparison of dose-intense gemcitabine: Thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma
M Tempero et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
分享论文
